Brief: Vincerx Pharma Announces FDA Safe To Proceed Letter For Investigational New Drug Application For Its aVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236
13/12/2022 15:33
Dec 13 (Reuters) - Vincerx Pharma Inc VINC.O :
* VINCERX PHARMA ANNOUNCES FDA SAFE TO PROCEED LETTER FOR
INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR ITS ΑVΒ3 SMALL
MOLECULE-DRUG CONJUGATE (SMDC) VIP236
* VINCERX PHARMA INC - PRECLINICAL STUDIES WITH VIP236
DEMONSTRATED PROMISING TUMOR REGRESSION IN IN VIVO CANCER MODELS
* VINCERX PHARMA INC - VIP236 FIRST-IN-HUMAN STUDY IN
ADVANCED OR
METASTATIC SOLID TUMORS ANTICIPATED TO COMMENCE IN Q1 2023
* VINCERX PHARMA INC - CONTINUE TO EXPECT CASH RUNWAY TO
LEAD INTO
LATE 2024
Source text for Eikon: ID:nGNX1NZf7w
Further company coverage: VINC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vincerx Pharma
See all newsBrief: Vincerx Pharma Announces Intent To Delist From Nasdaq And Deregister With The SEC
Brief: Vincerx Pharma Announces Termination Of Letter Of Intent And Board Authorization To Pursue Wind-Down Activities
Vincerx Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Vincerx Pharma Inc expected to post a loss of $3.40 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign